呼吸行业全景图：从呼吸1.0到呼吸4.0：剂型升级+机制创新点亮国货之光

Investment Rating - The industry investment rating is "Outperform the Market" [1][109]. Core Insights - The report outlines the evolution of the respiratory industry from "Respiratory 1.0" to "Respiratory 4.0," highlighting the impact of policy changes and formulation upgrades on the domestic market landscape [3][109]. - The report emphasizes the significant market potential for innovative targeted therapies in respiratory diseases, particularly in addressing unmet clinical needs [42][109]. - The integration of advanced technologies, such as AI, is expected to enhance drug discovery and development processes, particularly for complex diseases like idiopathic pulmonary fibrosis (IPF) [78][109]. Summary by Sections Respiratory 1.0 & 2.0 Era - The introduction of national centralized procurement has disrupted the oligopoly of foreign companies in the inhalation drug market, with domestic companies gaining market share [3][9]. - The inhalation drug market is evolving with the introduction of high-end formulations, such as aerosol and powder inhalers, which are expected to drive growth in the "Respiratory 2.0" era [19][25]. Respiratory 3.0 Era - The report identifies a wave of innovation in targeted therapies for chronic respiratory diseases, with leading domestic players actively pursuing new drug development [45][46]. - The global sales of innovative monoclonal antibodies for asthma treatment have reached significant levels, indicating a robust market opportunity for domestic companies [45][46]. Respiratory 4.0 Era - The report discusses the role of cutting-edge technologies in enabling the development of innovative drug targets, particularly in the context of precision medicine for respiratory diseases [84][105]. - The emergence of inhaled biologics and advanced delivery systems is expected to sustain long-term growth in the respiratory sector [104][105]. Investment Recommendations - The report suggests focusing on traditional respiratory leaders like China Biologic Products and Health元, as well as emerging players like Yuan Dong Biotech, which are well-positioned to capitalize on the evolving market landscape [109]. - It highlights the potential of new entrants in the pharmaceutical sector to leverage opportunities in the "Respiratory 3.0" era, recommending companies like Heng Rui Pharmaceutical and Shi Yao Group for investment consideration [109].